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AbstrAct:
Endogenous replicative stress could be one trigger leading to tumor initiation:  indeed, 
activation of the DNA damage response (DDR), considered the result of replicative 
stress, is observed in pre-cancerous cells; moreover, in hereditary breast cancers, 
almost all of the genes affected relate to the DDR. The most frequently mutated gene in 
hereditary breast cancers, BRCA1, is essential for homologous recombination (HR), a 
fundamental process for maintaining genome stability that permits the reactivation of 
blocked replication forks . Recent studies have established links between DDR and the 
oncogenic kinase AKT1, which is upregulated in about 50% of sporadic breast cancers. 
More specifically, the activation of AKT1 shows a deficient phenotype in BRCA1 and 
HR, revealing molecular similarities between hereditary and sporadic breast cancers. 
However, these results reveal a paradox regarding the physiological role of AKT1: in 
non-tumor cells, AKT1 promotes cellular proliferation, but consequently endangers 
genome integrity during replication if HR is inhibited. Since HR could itself lead to genetic 
instability, we propose that, under physiological conditions, moderate activation of 
AKT1 does not inhibit but prevents an excess of HR. The regulation of AKT1 would 
represent  a  fine  transitory  system  for  controlling  HR  and  maintaining  genomic  integrity.
The coordination of a complex network of metabolic 
pathways ensures continued maintenance, duplication, 
and transmission of the genome. These metabolic 
pathways control the DNA damage response pathway 
(DDR) and bring together replication, recombination, 
DNA repair, chromosome segregation, and cell cycle 
control. However, in some common tightly-regulated 
processes, such as meiosis and the generation of the 
immune repertory, this network must allow/favor genetic 
diversity. Therefore, very precise regulation is necessary 
to control the equilibrium between genetic stability and 
diversity, while avoiding genetic instability. A defect in 
any of the actors in these pathways could result in genetic 
instability and a predisposition to tumor formation.
Certain types of cancers correspond to areas 
exposed to oncogenic agents (often genotoxic), such as 
UV radiation for skin cancer or tobacco for throat or lung 
cancer. However, we emphasize that many cancers develop 
without substantial exposure to exogenous carcinogens. 
Therefore, endogenous stresses must play crucial roles in 
the etiology of cancer. For example, mutating the BRCA1 
or BRCA2 genes confers a hereditary predisposition to 
breast cancer in the absence of exposure to exogenous 
genotoxic agents.
the replicAtion/recombinAtion 
interfAce, genetic instAbility, 
And cAncer.
Among endogenous stresses, the spontaneous 
blocking of replication forks could constitute a risk for 
spontaneous tumor initiation. In fact, DNA replication 
forks are regularly blocked by a variety of endogenous 
stresses that can result from bulging regions in the DNA, 
regions of hybrid DNA/RNA, and from endogenous 
metabolism of the cell [1]. Furthermore, the prolonged 
arrest of these replication forks leads to the formation Oncotarget 2010; 1:  691 - 699 692 www.impactjournals.com/oncotarget
of double-strand breaks (DSBs) in the DNA, which can 
be taken care of by HR and non-homologous end-joining 
(NHEJ) [2-4]. It is therefore notable that the presence of 
DNA breaks and activation of the DDR pathway have 
been observed in the pre-cancerous stages of non-treated 
cells. This activation of the DDR pathway is considered 
the response to spontaneous replicative stress [5,6].
One example illustrating this point of view is Bloom 
syndrome, which results in an increased predisposition to 
spontaneous tumor formation in all tissues, even those that 
are not directly exposed. Bloom syndrome is caused by 
inactivation of the BLM protein, a RecQ member of the 
helicase family, which plays an important role in resolving 
HR intermediates and controlling blocked replication forks 
[7-9]. Furthermore, among the 11 genes whose germline 
mutations are responsible for predispose to familial breast 
cancer, 10 are implicated in the DDR pathway [10,11]. 
Interestingly, the most frequently mutated genes, BRCA1 
and BRCA2, play essential roles in HR [12,13], an 
essential process for maintaining genome integrity. The 
ubiquitous existence of this process in all living organisms 
highlights its biological importance. HR allows the repair 
of DSBs in DNA (Figure 1), as well as the reactivation of 
blocked replication forks (Figure 2) [14-16].
About one century ago, Theodor Boveri proposed 
that tumors arose from clonal development of a single 
aneuploid cell. He also proposed that this aneuploidy 
arose from unequal chomosome segregation, due to the 
presence of supernumerary centrosomes [17,18]. More 
recently, aneuploidy has been observed in precancerous 
lesions and tissues adjacent to tumors, suggesting a role 
in tumorigenesis [19-23]. This observation is therefore 
similar to activation of the DDR pathway and the 
detection of DSBs (see above). Centrosome duplication 
figure 1: A model for double-strand break repair by homologous recombination [78]. a) A DSB in the DNA generates regions 
of ssDNA. This step is promoted by the RAD50/MRE11/NBS1 complex associated with CtIP in mammals [79-82]. b) ssDNA is covered by the 
RPA (Replication protein A) protein. c) RAD52 (in yeast) or BRCA2 (in mammals) displaces RPA from the ssDNA and loads the key protein 
for HR, RAD51. d) The ssDNA-RAD51 complex finds the intact homologous double-stranded DNA and promotes the exchange of identical 
strands and the hybridization of complementary strands. e) DNA polymerase fills in the gap and moves the displacement loop (D-loop). f) The 
cruciform junctions (Holliday junctions) are then formed. g) The resolution of the Holliday junctions depends on the direction of resolution and 
can proceed via the following two mechanisms: without crossing over or with crossing over (exchange of adjacent DNA sequences).Oncotarget 2010; 1:  691 - 699 693 www.impactjournals.com/oncotarget
and genome replication should be coordinated to ensure 
faithful chrosomes segregation and exogenous stress that 
arrest replication generates supernumerary centrosomes 
[24-26]. It remains to be determined whether endogenous 
replicative stress and the presence of supernumerary 
centrosomes, which leads to aneuploidy, are connected at 
the molecular level and by what mechanisms. HR could 
be the link between these two processes. In fact, cells 
deficient  in  HR  demonstrate  both  replicative  stress,  as 
characterized by a slowing of the replication speed [27] 
and an increased frequency of cells with supernumerary 
centrosomes [28-32]. It should be noted that these defects 
have been observed regardless of the HR gene affected, 
among them the tumor suppressor genes BRCA1 and 
BRCA2.
Finally, it is important to emphasize that the 
communication between replication and recombination 
could represent an effective target for anti-cancer 
therapeutics. In fact, PARP inhibitors generate replicative 
stress, leading to the formation of DSBs; tumors deficient 
in HR, such as those with defects in BRCA1 or BRCA2, 
would therefore be highly sensitive to these inhibitors 
[33,34].
fAmiliAl versus sporAdic 
breAst cAncers: AKt1 And the 
deregulAtion of brcA1.
At present, the majority of mutations that confer 
figure 2: examples of the role of hr in restarting blocked replication forks [14-16]. a. A DSB can be generated by the collapse 
of a replication fork, for example due to a nick in the matrix. HR allows replication to restart by reinitiating it on the sister chromatid. b. When 
a fork reaches a blocking lesion, it can be reverted by generating a so-called “chickenfoot” structure. b-1. This structure has a DSB that can 
be used to initiate HR upstream of the blockage (given that the sequences are homologous). b-2. Alternatively, the cruciform structure can be 
resolved by specific endonucleases, which also generate DSBs. Replication can then be reactivated by HR using the sister chromatid. Oncotarget 2010; 1:  691 - 699 694 www.impactjournals.com/oncotarget
a predisposition to familial breast cancer affect genes 
implicated  in  DDR,  specifically  at  the  interface  of 
replication and recombination. The most frequently 
mutated gene, BRCA1, plays an important role in HR 
[12,35]. This overrepresentation of genes implicated in a 
particular pathway highlights the importance of the DDR 
pathway and the communication between replication 
and recombination in the etiology of breast cancer. This 
begs the question of whether the etiology of sporadic 
breast cancers shares the same mechanisms as those of 
hereditary breast cancers. This question is perhaps more 
relevant because sporadic cases of breast cancer are far 
more common than hereditary cases; in fact, hereditary 
breast cancer are consider to represent 5 to 10 %, and 
mutation of BRCA1 1 to 2%, of all cases [36,37]. 
The extremely diverse characteristics of tumors grouped 
in a common category (for example, the set of spontaneous 
breast cancers) represent an important obstacle to 
understanding the underlying molecular mechanisms in an 
unifying view. However, it is noteworthy that, in a number 
of studies, the oncogenic kinase AKT1 has been shown to 
be upregulated in 40-60% of sporadic breast cancers and 
40% of sporadic ovarian cancers [38-40]. Furthermore, 
AKT1 can phosphorylate BRCA1 in vitro [41]. Therefore, 
it is important to determine whether the activation of 
AKT1 in sporadic cancers leads to a phenotype similar to 
that observed in familial cancers.  AKT1  is  involved 
in the PI3 Kinase/PTEN/AKT1 signaling pathway and 
responds to extracellular stimuli, including growth factors 
and hormones [42]. PTEN is a tumor suppressor gene and 
an antagonistic inhibitor of AKT1 (inactivation of PTEN 
leads to the activation of AKT1). It is noteworthy that i) 
PTEN is one of the mutated genes in familial breast cancers 
[43,44], and decreased amount of the PTEN protein is 
observed in 25% of breast cancers [45]; ii) mutations in 
PTEN are associated with Cowden syndrome, in which 
the probability of developing breast cancer reaches 30% 
[46]; iii) the inactivation of PTEN leads to an increase 
in genetic instability [47-50]; iv) cells lacking PTEN 
show elevated levels of spontaneous DSBs [49,50] and 
decreased expression of the recombinase RAD51 [50-52], 
which lead to the defective repair of DSBs by HR; and 
v) tumors or cells lacking PTEN are sensitive to PARP 
inhibitors [52,53].
Rencently, several studies have been demonstrating 
a relationship between AKT1 and DDR. For instance, 
AKT1 destabilizes p53 via the phosphorylation of Mdm2 
[54]; AKT1 controls the basal expression of XRCC1 [55]; 
the activation of AKT1 leads to the sequestration of CHK1 
to the cytoplasm [47-49], and AKT1 phosphorylates and 
prevents the activation of CHK1 by ATR/ATM [56]; 
finally, AKT1 reduces the abundance of γ-gH2AX foci 
[57,58] in asynchronous cells, and inhibits the activation 
of CHK1 and the repair of DSBs at the end of G2 [59]. 
More directly related to the questions discussed here, 
the overexpression of AKT1 has been shown to promote 
the sequestration of BRCA1 and RAD51 to the cytoplasm 
[38,60]. This sequestration of BRCA1 and RAD51 to 
the cytoplasm has been observed both in cultured cell 
lines and in 60% of sporadic breast cancer tumors, in 
which it is correlated with the level of AKT1 activation 
[38]. Delocalizing BRCA1 and RAD51 to the cytoplasm 
inhibits the nuclear functions of BRCA1, such as the 
recruitment to sites of damage after exposure to ionizing 
radiation and the control of HR. Consistent with the 
phenotype of cells that are mutated in components of HR, 
cells overexpressing AKT1 have a higher frequency of 
supernumerary centrosomes [60]. Furthermore, the AKT1 
signaling pathway negatively regulates the expression of 
BRCA1 mRNA [61]. Therefore, the over-activation of 
AKT1, which occurs in about half of all sporadic breast 
cancers, leads to a phenotype similar to that of brca1-
/- cells, without the need for mutating the BRCA1 gene. 
Moreover, it seems, that a lack of BRCA1 is linked to a 
constitutive activation of the AKT1 signaling pathway. 
Because BRCA1 is the most frequently mutated gene in 
hereditary breast cancers, the relationship between AKT1 
and BRCA1 could constitute the missing molecular link 
between sporadic and familial breast cancers.
Conversely, BRCA1 negatively regulates AKT1 by 
inducing its degradation [61]. In addition, a lack of BRCA1 
activates the AKT1 pathway by causing disappearance of 
the PTEN protein, which is observed in 82% of hereditary 
breast cancers linked to BRCA1 [62].
Epidemiological studies have concluded that 
hormone substitution leads to an increased risk for breast 
cancer [63-65]. Because AKT1 activity is inducible by 
hormones [66,67], it is tempting to speculate that, for 
certain people, hormonal treatments could lead to high and 
chronic activation of AKT1, thus altering the functions of 
BRCA1, and therefore to predispose to breast cancer.
The negative impact of AKT1 on HR and on BRCA1 
localization, resulting in  a  BRCA1-deficient phenotype 
(without requiring mutation in the BRCA1 gene) suggests 
that tumors with hyperactivated AKT1 might be sensitive 
to PARP inhibitors. In agreement with this model, PTEN 
deficient  tumors  are  hypersensitive  to  PARP  inhibitors 
[52]. Therefore the high frequency of AKT1 activation in 
sporadic breast cancer opens promizing new avenues for 
therapy. However, because AKT1 activation also protects 
against cell death and because of the highly pleiotropic 
regulation of AKT1, the molecular characterization of 
AKT1 impact on HR becomes an essential issue.
the pArAdox of AKt1: A rheostAt 
of hr?
The inhibition of HR by AKT1 is mechanistically 
consistent with its role in breast cancer, i.e., under 
pathological conditions. However, under physiological 
conditions, this reveals a paradox, notably in response 
to growth factors, because AKT1 plays a role in cellular Oncotarget 2010; 1:  691 - 699 695 www.impactjournals.com/oncotarget
proliferation (for a review, see [68]). A number of studies 
have demonstrated that the PI3K pathway is involved in the 
G1 to S phase transition via i) the inactivation of GSK3β, 
and the stabilization of cyclin D and c-myc, ii) inhibition 
of the Forkhead family of transcription factors leading to a 
decrease in p27Cip1, and iii) inactivation of p21 and p27 via 
direct phosphorylation by AKT1 [68]. Because cellular 
proliferation requires genome replication, the inhibition 
of HR by the activation of AKT1 thus presents a risk to 
maintaining genome stability. Two possible solutions can 
resolve this paradox:
1- level and duration of AKt1 activation.
We must point out that the level and duration of 
AKT1 activation are very different between physiological 
and pathological conditions. The activation of AKT1 
is moderate and mostly transient under physiological 
conditions, but is stronger and constant (generally due 
to upstream deregulation, e.g., the inactivation of PTEN) 
under pathological conditions, thus accounting for the 
pathological phenotype. For example, the activation of 
AKT1 by a growth factor (heregulin β1) or by hormones 
(IGF-1 and estrogen) (in other words, physiological 
figure 3: genetic instability linked to excess of homologous recombination. A. Chromosomal rearrangements resulting from 
crossing over (CO). 1. CO between repetitive sequences on two chromosomes or during an unequal sister chromatids exchange, resulting in 
an amplification on one molecule and a deletion on the other. 2. Intra-chromatid CO between two direct repeats, resulting in excision of the 
internal fragment. 3. Intra-chromatid CO between inversely oriented sequences, resulting in inversion of the internal fragment. 4. and 5. Inter-
chromosomal CO. Depending on the orientation of the sequence with respect to the centromere (blue or red circles), the process will generate a 
translocation (4) or a dicentric chromosome and an acentric chromosome (5). B. Genetic modifications resulting from gene conversion without 
crossing over. Top: between two heteroalleles, leading to a loss of heterozygosity. Bottom: gene conversion between a pseudogene (hatch-
marked), which often contains stop codons, and a gene, resulting in inactivation of the gene. Mutations are shown in red.Oncotarget 2010; 1:  691 - 699 696 www.impactjournals.com/oncotarget
activation mechanisms) promotes the nuclear localization 
of BRCA1 [69,70]. Moreover it is also reasonable to 
suggest that the consequences of AKT1 activation may 
vary based on cell type.
2- risk of excess hr initiation on genetic stability
If HR is an essential process for maintaining genome 
integrity, it is also a double-edged sword, because it can 
also generate genetic instability:
A  -  On one hand, defects in HR lead to 
genetic instability and increased mutagenesis. 
On the other hand, the genome contains many 
repetitive sequences, and HR between these sequences 
can lead to chromosomal rearrangements and therefore 
genetic instability (Figure 3). Severe chromosomal 
rearrangements, such as deletions, inversions, duplications, 
and translocations requiring repetitive sequences have 
been observed in various human pathologies [71-74].
B  -  Unresolved HR intermediates are toxic 
and can generate genetic instability [75].
Therefore,  maintaining  genome  stability  benefits 
from the avoidance of excess HR initiation. This point is 
especially crucial during the S phase, because HR occurs 
preferentially during the S phase [76,77]. In addition, 
the substrate for HR is single-stranded DNA (ssDNA) 
covered with the RPA protein (Figure 1). Because RPA 
is a protein implicated in replication, RPA complexed 
to ssDNA is present throughout the genome during 
replication. If HR were initiated every time that RPA 
bound to ssDNA, it would lead to complete disruption 
of the genome. Therefore, it is necessary to precisely 
control recombination to maintain genome stability and 
avoid genetic instability, particularly during S phase. 
Signaling downstream of the ssDNA-RPA complex might 
be different in the replication vs. the HR intermediates, 
following the resection step. Moreover, helicases have been 
shown participate to the maintenance of genome stability 
by disrupting abortive HR intermediate [75]. However, it 
is necessary to precisely control recombination at multiple 
levels to maintain genome stability, particularly during S 
phase. We propose that AKT1 is an upstream regulator by 
preventing the excess of HR initiation.
3- A potential role for AKt1 under physiological 
conditions.
The previous explanations suggest that in non-
stressed cells, the transient and moderate activation of 
AKT1 avoids excess HR, which could be harmful to 
genome stability, without completely repressing it. The 
activation of AKT1 by extracellular factors (growth 
factors, hormones, interleukins), which depends on the 
combination and concentration of these extracellular 
factors, and of the cellular receptors of these factors, should 
therefore allow for a subtle and transitory regulation of 
HR. Under physiological conditions, AKT1 would play a 
role as a rheostat to precisely regulate HR. For example, 
in human fibroblasts, the growth factor FGF (fibroblast 
growth factor) activates AKT1 and represses excess HR 
without inhibition of HR; in fact, the level of HR never 
decreases by more than 50% of the level in non-stimulated 
cells [38]. In contrast, the strong and constant activation 
of AKT1 must strongly affect the subtle regulation of 
HR, leading to an important disequilibrium and the 
complete inhibition of HR, thus promoting an abnormal 
or pathological condition.
The characterization of the molecular mechanisms 
that allow AKT1 to modulate HR, and more generally 
DNA repair, represents an important focus of future 
research. Uncovering these processes will allow better 
understanding of the mechanisms that maintain genetic 
stability and result in spontaneous tumor development and 
to optimize cancer therapy.
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